European Heart Journal · 2015 · 84 citations · 17 references
MedicinePharmacologyPharmacotherapyPain MedicinePharmacogeneticsPharmacogenomicsCardiac MedicationsOpioid AnalgesicsOpioid ManagementOpioid PharmacologyOpioid TherapyPharmacogenomics In CardiologyAnalgesic Efficacy AssessmentAntiplatelet DrugsBaseline Risk DifferencesIn-hospital MortalityMyocardial Infarction GeneticsNon-st-elevation Myocardial InfarctionOpioid PharmacogeneticsPharmacological Pain Relief
AIMS: The use of opioids is recommended for pain relief in patients with myocardial infarction (MI) but may delay antiplatelet agent absorption, potentially leading to decreased treatment efficacy. METHODS AND RESULTS: In-hospital complications (death, non-fatal re-MI, stroke, stent thrombosis, and bleeding) and 1-year survival according to pre-hospital morphine use were assessed in 2438 ST-elevation MI (STEMI) patients from the French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2010. The analyses were replicated in the 1726 STEMI patients of the FAST-MI 2005 cohort, in which polymorphisms of CYP2C19 and ABCB1 had been assessed. Specific subgroup analyses taking into account these genetic polymorphisms were performed in patients pre-treated with thienopyridines. The 453 patients (19%) receiving morphine pre-hospital were younger, more often male, with a lower GRACE score and higher chest pain levels. After adjustment for baseline differences, in-hospital complications and 1-year survival (hazard ratio = 0.69; 95% confidence interval: 0.35-1.37) were not increased according to pre-hospital morphine use. After propensity score matching, 1-year survival according to pre-hospital morphine was also similar. Consistent results were found in the replication cohort, including in those receiving pre-hospital thienopyridines and whatever the genetic polymorphisms of CYP2C19 and ABCB1. CONCLUSION: In two independent everyday-life cohorts, pre-hospital morphine use in STEMI patients was not associated with worse in-hospital complications and 1-year mortality. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00673036 (FAST-MI 2005); NCT01237418 (FAST-MI 2010).
17
Clinical End Points in Coronary Stent Trials
Donald E. Cutlip, Stephan Windecker, Roxana Mehran et al. · Circulation · 2007 · 5.4K citations
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Tabassome Simon, Céline Verstuyft, Murielle Mary‐Krause et al. · New England Journal of Medicine · 2008 · 1.7K citations · Full text
Medicine, Genetics, Pharmacology +17